Analysis based on projected data indicates a consistent, albeit slight, decline in sales of modulators of the genital system and sex hormones in Canada from CAD 753.5 million in 2024 to CAD 744.8 million by 2028. The year-on-year variations are as follows:
- 2025: -0.39%
- 2026: -0.32%
- 2027: -0.25%
- 2028: -0.20%
The CAGR (Compound Annual Growth Rate) over this period is estimated at -0.29% per year.
Future trends to watch include advancements in biotechnology, shifting regulatory landscapes, and potential market expansions due to aging populations and increasing awareness of hormonal treatment options. Monitoring competitive dynamics and therapeutic innovations will be critical for understanding market fluctuations.
